Study on potential molecular mechanism of Mongolian medicine Bawei Sanxiang San in treatment of chronic heart failure based on network pharmacology and molecular docking.
10.19540/j.cnki.cjcmm.20210125.401
- Author:
Ying-Lu BAI
1
;
Jin-Fang ZHANG
1
;
Zi-Jun SHA
1
;
Na ZHU
1
;
Xiu-Lan HUANG
1
;
Zhi-Yong LI
1
Author Information
1. Key Laboratory of Ethnic Medicine of Ministry of Education, School of Pharmacy,Minzu Universuty of China Beijing 100081, China.
- Publication Type:Journal Article
- Keywords:
Bawei Sanxiang San;
Mongolian medicine;
chronic heart failure;
molecular docking;
network pharmacology
- MeSH:
Drugs, Chinese Herbal;
Heart Failure/genetics*;
Humans;
Medicine, Chinese Traditional;
Medicine, Mongolian Traditional;
Molecular Docking Simulation
- From:
China Journal of Chinese Materia Medica
2021;46(10):2392-2402
- CountryChina
- Language:Chinese
-
Abstract:
To explore the potential molecular mechanism of Mongolian medicine Bawei Sanxiang San in the treatment of chronic heart failure(CHF) through network pharmacology and molecular docking technology. The active ingredients and potential targets of Bawei Sanxiang San were collected by applying TCMSP, BATMAN databases and literature mining. CHF-related genes were collected through TTD, GeneCards and CTD databases. After the potential common targets between Bawei Sanxiang San and CHF were disco-vered, the interaction network diagram of "compound-target-pathway" was constructed using Cytoscape. The intersecting targets were imported into the DAVID database for GO function and KEGG pathway enrichment analysis. Finally, the Autodock_vina software was used to molecularly dock the selected proteins with the active ingredients of Bawei Sanxiang San. The results showed that there were 60 active ingredients in Bawei Sanxiang San that might be used to treat CHF, involving 311 target genes and 7 signaling pathways that directly related to CHF, such as HIF-1 signaling pathway, TNF signaling pathway, adrenergic signaling in cardiomyocytes, aldosterone-regulated sodium reabsorption, calcium signaling pathway, cGMP-PKG signaling pathway, renin secretion. Additionally, molecular docking showed that the bioactive compounds had good binding activity with the protein receptors of key target genes. Bawei Sanxiang San might exert therapeutic effects on CHF by regulating cardiomyocytes, angiogenic and inflammation related targets and pathways in a multi-component, multi-target and multi-pathway manner.
